

MAR 05 2002

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Approved for use through 10/31/2002. OMB 0651-0031

PTO/SB/30 (10-01)

**REQUEST
FOR
CONTINUED EXAMINATION (RCE)
TRANSMITTAL**Address to:
Commissioner for Patents
Box RCE
Washington, DC 20231

Application Number	09/089,583
Filing Date	06/03/1998
First Named Inventor	WEISMAN, Kenneth M.
Art Unit	1623
Examiner Name	OWENS, Jr., Howard V.
Attorney Docket Number	W1068/20011

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. **Submission required under 37 CFR 1.114**a. ☐ Previously submittedi. ☐ Consider the amendment(s)/reply under 37 CFR 1.116 previously filed on _____
(Any unentered amendment(s) referred to above will be entered).ii. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____iii. ☐ Other _____b. ☒ Enclosedi. ☒ Amendment/Replyii. ☐ Affidavit(s)/Declaration(s)iii. ☐ Information Disclosure Statement (IDS)iv. ☐ Other _____2. **Miscellaneous**a. ☐ Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required.)b. ☐ Other _____3. **Fees**a. ☒ The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.Deposit Account No. 03-0075i. ☒ RCE fee required under 37 CFR 1.17(e) (\$370.00)ii. ☐ Extension of time fee (37 CFR 1.136 and 1.17)iii. ☐ Other _____b. ☐ Check in the amount of \$ _____ enclosedc. ☐ Payment by credit card (Form PTO-2038 enclosed)**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.****SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED**

Name (Print/Type)

Alan H. Bernstein

Registration No. (Attorney/Agent)

19,315

Signature

Date

2/25/02

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Box RCE, Washington, DC 20231, or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Name (Print/Type)

Alan H. Bernstein

Signature

Date

2/25/02

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND Fees and Completed Forms to the following address: Assistant Commissioner for Patents, Box RCE, Washington, DC 20231.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT EXAMINING OPERATION

C/20
10/27
6/2/02

RECEIVED
MAR 08 2002
TECH CENTER 1600/2900

Applicant : Kenneth Weisman and
Michael E. Goldberg
Serial No. : 09/089,583
Filed : June 3, 1998
Title : METHOD OF DECREASING
ATHEROSCLEROSIS AND ITS
COMPLICATIONS
Examiner : Howard Owens
Group Art Unit : 1614
Docket No. : W1068/20011
Customer No. : 03000

RECEIVED

AMENDMENT ACCOMPANYING THE FILING
OF REQUEST FOR CONTINUED EXAMINATION

MAY 20 2002

TECH CENTER 1600/2900

Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:

In response to the final Office Action mailed on December 20, 2002, please
amend the application as follows:

Please add the following claims:

15. A method of decreasing atherosclerosis comprising administering to an
animal or human an amount of a substance which acts to decrease the levels of
testosterone or which inhibits the actions of testosterone.

16. A method of decreasing atherosclerosis comprising administering to a
human or an animal an amount of a substance selected from the group consisting of